Desmopressin vs Omentin-1
Head-to-head comparison of Desmopressin (1-Deamino-8-D-arginine vasopressin) and Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Desmopressin | Omentin-1 |
|---|---|---|
| Category | Cognitive Enhancement | Diabetes & Metabolic |
| Full Name | 1-Deamino-8-D-arginine vasopressin | Omentin-1 (Intelectin-1, ITLN1) |
| Molecular Weight | 1069.22 Da | ~35 kDa |
| Half-Life | 1.5-3 hours | hours |
| Amino Acids | 9 | 313 |
| Typical Dose | 10-40 mcg intranasal | No approved human dose; research use only |
| Route | Intranasal/Oral | IV|SC |
| Purity | ≥98% | ≥98% |
| Studies Count | 35 | 82 |
| Research Status | Clinical | Pre-clinical |
Desmopressin Benefits
- ✓memory consolidation
- ✓reduced pressor burden
- ✓recall support
- ✓short-term learning
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Desmopressin Dosing
intranasal research dosing|10-40 mcg or IU-equivalent studies|single-dose protocols
Omentin-1 Dosing
not established|not established
Desmopressin Side Effects
- ⚠hyponatremia
- ⚠headache
- ⚠nasal irritation
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Research Overview
Desmopressin
The literature is mixed, but desmopressin has shown memory-related effects in selected populations and experimental paradigms. Its cognitive effects are usually discussed as a vasopressin-pathway probe rather than a primary nootropic.
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.